Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NTRA
stocks logo

NTRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
576.45M
+21.09%
-0.515
+25.69%
609.22M
+21.4%
-0.559
+11.77%
631.35M
+15.5%
-0.519
-29.93%
Estimates Revision
The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 6.04% over the past three months. During the same period, the stock price has changed by 44.07%.
Revenue Estimates for FY2025
Revise Upward
up Image
+6.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+24.27%
In Past 3 Month
Stock Price
Go Up
up Image
+44.07%
In Past 3 Month
Wall Street analysts forecast NTRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast NTRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 242.060
sliders
Low
172.00
Averages
233.50
High
280.00
Current: 242.060
sliders
Low
172.00
Averages
233.50
High
280.00
JPMorgan
NULL -> Overweight
maintain
$240 -> $250
2025-11-25
Reason
JPMorgan
Price Target
$240 -> $250
2025-11-25
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Natera to $250 from $240 and keeps an Overweight rating on the shares. The firm updated the company's model.
UBS
Buy
upgrade
$218 -> $280
2025-11-18
Reason
UBS
Price Target
$218 -> $280
2025-11-18
upgrade
Buy
Reason
UBS raised the firm's price target on Natera to $280 from $218 and keeps a Buy rating on the shares.
Stephens
Stephens
Overweight
maintain
$17 -> $235
2025-11-13
Reason
Stephens
Stephens
Price Target
$17 -> $235
2025-11-13
maintain
Overweight
Reason
Stephens raised the firm's price target on Natera to $235 from $17 and keeps an Overweight rating on the shares after the company reported "another strong beat." The firm continues to view Natera as "one of the most attractive organic growth stories" within diagnostics, the analyst tells investors.
Stephens
Stephens
Overweight
maintain
$197 -> $235
2025-11-13
Reason
Stephens
Stephens
Price Target
$197 -> $235
2025-11-13
maintain
Overweight
Reason
Stephens raised the firm's price target on Natera to $235 from $197 and keeps an Overweight rating on the shares after the company reported "another strong beat." The firm continues to view Natera as "one of the most attractive organic growth stories" within diagnostics, the analyst tells investors.
Morgan Stanley
NULL -> Overweight
maintain
$195 -> $220
2025-11-11
Reason
Morgan Stanley
Price Target
$195 -> $220
2025-11-11
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Natera to $220 from $195 and keeps an Overweight rating on the shares.
Piper Sandler
Overweight
maintain
$220 -> $230
2025-11-11
Reason
Piper Sandler
Price Target
$220 -> $230
2025-11-11
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Natera to $230 from $220 and keeps an Overweight rating on the shares. The firm cites the company's quarterly results for the price target change.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Natera Inc (NTRA.O) is -118.84, compared to its 5-year average forward P/E of -38.34. For a more detailed relative valuation and DCF analysis to assess Natera Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-38.34
Current PE
-118.84
Overvalued PE
-4.32
Undervalued PE
-72.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-40.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.93
Undervalued EV/EBITDA
-77.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.03
Current PS
0.00
Overvalued PS
13.13
Undervalued PS
4.92
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 265.72% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

NTRA News & Events

Events Timeline

(ET)
2025-12-01
16:40:00
Morgan Stanley Initiates Coverage on Natera with Overweight Rating, Price Target Raised to $265
select
2025-11-06 (ET)
2025-11-06
16:37:51
Natera projects FY25 revenue between $2.18B and $2.26B, surpassing consensus estimate of $2.09B.
select
2025-11-06
16:37:20
Natera Announces Q3 Earnings Per Share of 64 Cents, Exceeding Consensus Estimate of 35 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-03Newsfilter
Natera Presents Signatera Data, Enhancing Lymphoma Monitoring Efficacy
  • Clinical Validity Enhancement: Natera will present new data on Signatera at the 2025 ASH Annual Meeting, covering a real-world cohort of 144 patients, suggesting broad applicability in monitoring treatment responses in lymphoma, which could significantly improve personalized treatment outcomes for patients.
  • Early Recurrence Detection: Signatera outperformed standard imaging methods in detecting recurrences, enabling earlier identification before imaging, thereby enhancing clinical decision-making in disease management and potentially improving patient prognosis.
  • Response Assessment: Personalized ctDNA detection at the end of treatment and during treatment clearance has been shown to be strong predictors of clinical outcomes across multiple lymphoma subtypes, which not only boosts confidence in standard therapies but may also drive the incorporation of ctDNA-MRD into NCCN guidelines.
  • Commitment to Precision Oncology: Natera's Chief Medical Officer emphasized that the data from Signatera highlights the company's commitment to advancing precision oncology for blood cancers, which is expected to further drive market demand for personalized medicine.
[object Object]
Preview
3.5
12-02Newsfilter
Natera's Signatera Achieves 100% Sensitivity and Specificity in Breast Cancer Recurrence Detection
  • Detection Accuracy: Natera's Signatera achieved 100% sensitivity and specificity in detecting breast cancer recurrence among 227 patients, indicating its potential in clinical monitoring to significantly enhance early intervention success rates.
  • Risk Assessment: Patients who tested positive for Signatera within three months post-surgery exhibited a significantly higher risk of distant recurrence (HR: 13.1), providing crucial prognostic information that aids in developing personalized treatment plans.
  • Clinical Trial Results: The LEADER trial demonstrated that patients with sustained MRD negativity maintained a 99% disease-free survival rate over 12 months, while MRD-positive patients initiating ribociclib treatment showed significant ctDNA reduction, delaying distant recurrence onset.
  • Data Presentation: Natera will present data from over 50,000 patients at the 2025 San Antonio Breast Cancer Symposium, emphasizing Signatera's prognostic and predictive capabilities across various breast cancer subtypes, further solidifying its leadership in precision medicine.
[object Object]
Preview
2.0
11-23Benzinga
Top 10 Large-Cap Gainers Last Week (Nov. 17-Nov. 21): Alphabet, Exact Sciences, and Regeneron Lead the Pack—Is Your Portfolio Included?

  • Top Stock Performers: Exact Sciences Corporation surged 48.97% after Abbott Laboratories announced its acquisition for $105 per share, while other notable gainers included Jazz Pharmaceuticals (3.75%), Natera (12.90%), and Amer Sports (12.86%) due to positive financial results and analyst upgrades.

  • Analyst Ratings and Forecasts: Natera received a price forecast increase from UBS, Amer Sports raised its FY25 guidance, and Lumentum Holdings was initiated with an Outperform rating and a price target of $290 by Mizuho.

  • Acquisitions and Buybacks: Solventum Corporation announced its acquisition of Acera Surgical for $725 million and a $1 billion stock buyback plan, while Guardant Health and Regeneron Pharmaceuticals also saw significant gains this week.

  • Regulatory Challenges for Alphabet: Alphabet Inc. gained 4.9% as it criticized the DOJ's proposal to break up Google Ad Manager, arguing it would create uncertainty for advertisers and publishers while vowing to seek a resolution that supports business growth.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Natera Inc (NTRA) stock price today?

The current price of NTRA is 242.06 USD — it has increased 1.62 % in the last trading day.

arrow icon

What is Natera Inc (NTRA)'s business?

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

arrow icon

What is the price predicton of NTRA Stock?

Wall Street analysts forecast NTRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Natera Inc (NTRA)'s revenue for the last quarter?

Natera Inc revenue for the last quarter amounts to 592.18M USD, increased 34.66 % YoY.

arrow icon

What is Natera Inc (NTRA)'s earnings per share (EPS) for the last quarter?

Natera Inc. EPS for the last quarter amounts to -0.64 USD, increased 146.15 % YoY.

arrow icon

What changes have occurred in the market's expectations for Natera Inc (NTRA)'s fundamentals?

The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 6.04% over the past three months. During the same period, the stock price has changed by 44.07%.
arrow icon

How many employees does Natera Inc (NTRA). have?

Natera Inc (NTRA) has 4424 emplpoyees as of December 05 2025.

arrow icon

What is Natera Inc (NTRA) market cap?

Today NTRA has the market capitalization of 33.41B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free